Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04235257 · ClinicalTrials.gov registry record · Phase 4
Intradermal, Fractional Dose of HPV Vaccines:
A Phase 4 study of HPV Infection and HPV Vaccine, sponsored by University of Washington.
- Active
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT04235257: Active Phase 4 study of HPV Infection and HPV Vaccine, sponsored by University of Washington.
NCT04235257 is a Phase 4 study of HPV Infection and HPV Vaccine that is active but no longer recruiting, run by University of Washington. The registered enrollment target is 40 participants, below the 233-participant average among 13 other HPV Infection trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04235257, a Phase 4 study of HPV Infection and HPV Vaccine, is active but no longer recruiting, sponsored by University of Washington.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized phase IV trial compares fractional dose of bivalent HPV vaccine to fractional dose of nonavalent HPV vaccine among men and women aged 27-45 years in Seattle, Washington. Participants will have immune response assessed at baseline, 4 weeks, 6 months, 12 months, and 24 months.
Primary Outcome
HPV antibody response after delivery of a single, intradermal, fractional dose of the HPV-2 or HPV-9 vaccines
Conditions Studied
Interventions
- BIOLOGICAL HPV vaccine
Study Locations (1)
Washington
- University of Washington Virology Research Clinic - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2020-11-01 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 4 |
What the registry record for NCT04235257 still lists
NCT04235257 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 233-participant average among 13 other HPV Infection trials with a reported enrollment target (83% lower).
The record links to 2 conditions, with HPV Infection appearing as the primary indexed condition, and to 1 intervention - of which HPV vaccine is the first listed.
NCT04235257 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT04235257 about?
NCT04235257 is a clinical study titled "Intradermal, Fractional Dose of HPV Vaccines:". This randomized phase IV trial compares fractional dose of bivalent HPV vaccine to fractional dose of nonavalent HPV vaccine among men and women aged 27-45 years in Seattle, Washington. Participants will have immune response assessed at baseline, 4 weeks, 6 months, 12 months, and 24 months.
What is the current status of trial NCT04235257?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2020-11-01. Estimated completion is 2026-12-31.
What conditions does trial NCT04235257 study?
This clinical trial studies the following conditions: HPV Infection, HPV Vaccine.
What interventions are being tested in trial NCT04235257?
The interventions under investigation include: HPV vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT04235257?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04235257 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HPV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04235257's enrollment target sits among peer trials
40 11th of 13 higher than 3 of 13 other HPV Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HPV Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
RECRUITING · Phase 4
-
Immunogenicity of Fractional Dose of the HPV Vaccines
ACTIVE NOT RECRUITING · Phase 4
-
An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen
ACTIVE NOT RECRUITING · Phase 4
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
PCOM2 - The Physician Communication Intervention, Version 2.0
RECRUITING · NA
-
Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI